Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while Royalty Pharma plc Class A Ordinary Shares trades at $59.03 (market cap $25.18B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 8.8× Dyne Therapeutics Inc. Common Stock's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Royalty Pharma plc Class A Ordinary Shares for 6 Days on average.
| DYN | RPRX | |
|---|---|---|
Market Cap | $2.86B | $25.18B |
Volume | 3,341,579 | 3,399,248 |
Sector | Health | Health |
52-Week High | $26.78 | $63.96 |
52-Week Low | $14.60 | $36.18 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.18B | $32.42B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Royalty Pharma (RPRX) trades at $56.57, down 2.09% on the day, with a bullish technical signal and strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue and net income show steady growth, supported by a high gross profit margin of 89.38%. Analyst consensus is unanimously bullish with a $63.33 price target.
The outlook remains positive given earnings momentum and strategic capital deployment, though risks include biopharma policy shifts and reliance on partner drug performance. The stock offers exposure to a diversified portfolio of blockbuster drugs with minimal operational risk, but investors should monitor upcoming earnings and broader sector dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
